caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1770697542

Namita SoodM.D.

Pulmonary DiseaseSacramento, CAI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
REFERRAL NETWORK

Where Namita Sood's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 16 inbound referrers · 0 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
OHIO STATE UNIVERSITY HOSPITALS1731,003
DEDELOW, JEFFREY47135
ARTHUR G JAMES CANCER HOSPITAL AND RESEARCH INSTITUTE2679
John Larry
Cardiology · Columbus, OH
2064
Mauricio Stanzione Galizia
Diagnostic Radiology · Ann Arbor, MI
1943
Joseph Yu
Diagnostic Radiology · Columbus, OH
1642
Martha Gulati
Cardiology · Los Angeles, CA
1425
Jonathan Parsons
Pulmonary Disease · Columbus, OH
1430
Maria Lucarelli
Pulmonary Disease · Columbus, OH
1435
Ruchika Husa
Cardiology · Denver, CO
1331
Serge Nana-Sinkam
Pulmonary Disease · Richmond, VA
1328
Philip Diaz
Pulmonary Disease · Columbus, OH
1374
Refers patients to
Outbound — where patients go next
No outbound pairs above the suppression threshold.
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
679
Unique beneficiaries
—
Total services
998
Distinct HCPCS
14
Medicare payment
$66K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 901 Pulmonary Disease providers in CA — above median (cohort median 927).
PRESCRIBING · PART D · 2024
Total Rx claims
2,827
Beneficiaries
—
Total drug cost
$12.1M
Distinct drugs
36
Brand share
36.0%
Top prescribed drugs
Ambrisentan360 claims
Nintedanib Esylate305 claims
Spironolactone208 claims
Riociguat187 claims
Tadalafil184 claims
QUALITY · MIPS · 2024
Final MIPS score
83.2
Quality
64.8
Cost
68.7
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
0.34%
Group
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
Total received
$43K
Payment records
54
By payment type
Consulting Fee$18K
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$17K
Travel and Lodging$5K
Food and Beverage$2K